BioCorRx Inc. · OTC:BICX
BioCorRx — Investor Presentation (March 2018)
31 slides from BioCorRx's investor presentation, Mar 1, 2018
Slide 1: BioCorRx
4 | BioCorRx
Slide 2: Safe Harbor Statement
SSS sss ss) BioCorRxef Safe Harbor Statement ‘The information in this investor presentation may include forward-looking statements. These forward- looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forwa
Slide 3: Investment Highlights
SSS sss ss) BioCorRx g Investment Highlights ¥ The addiction treatment market represents a multi-billion dollar industry which is undergoing a radical transformation to new treatment modalities involving medications. Y BioCorRx has a two business models for treating addiction aligned with this chang
Slide 4: Company Overview
Company Overview Substance abuse and addiction treatment company offering a two-pronged approach to the treatment of substance abuse addiction BioCorRxef Holding Company BioCorRx Pharmaceuticals BioCorRxef Recovery Program ‘Commercialization of naltrexone implant: BICK102, focused on 505(b)(2) regul
Slide 5: The Addiction Epidemic
The Aadiction Epidemic Dev Gastating Costs, s, Imperfect Soluti
Slide 6: The Addiction Epidemic
SSS sss ss) BioCorRxef The Addiction Epidemic " Medication-assisted treatment (MAT) — the use of medication combined with counseling and behavioral therapies is ‘one of the major pillars of the federal response to the opioid epidemic in this country. This type of treatment is an important tool that
Slide 7: The Opioid Epidemic in the U.S.
BioCorRxeg & The Opioid Epidemic in the U.S. In 2016... B 12.5 million People misused prescription opioids’ f&2: million $& 33,091 23 2mMIllion #215281 828,000 #9580 7135000 12,989 People uted heron Daathe atibutd 1 for the fot ine” everdosing on heroin”* Gres billion In economic costs (2013 cata)*
Slide 8: Addiction Treatment Market
SSS sss ss) BioCorRx g Addiction Treatment Market: Addiction treatment spending has grown faster than the total GDP inflation rate, the medical care inflation rate, and population growth. From 2008- 2014, growth in addiction treatment spending also exceeded growth in total health spending. Spending
Slide 9: Medication Assisted Treatment
et BioCorRx of Medication Assisted Treatment Strong shift towards combining medication and counseling “By its very definition, medication-assisted treatment has to include more than medication alone. It has to include counseling services and the other support services that are an important part of e
Slide 10: The Big Three
ee BioCorRx g The Big Three The Most Common MAT Medications Include: 1) Methadone: + FDAapproved + Narcotic and addictive — significant withdrawals when ceasing use + Daily Dose *+ Opioid Derived (full agonist) 2) Suboxone/Buprenorphine + FDA approved + Narcotic and addictive significant withdrawals
Slide 11: Naltrexone Science
Naltrexone Science Naltrexone is a unique medication which binds with receptors and prevents the release of Dopamine — reducing cravings for alcohol and drugs Naltrexone was approved by the FDA in 1984, in tablet form, for opioid addiction and approved subsequently in 1994 for alcohol use disorders
Slide 12: Pipeline
t Pipeline Unlocking Value, Expanding Treatment Capacity
Slide 13: BioCorRx Pharmaceuticals: Naltrexone Implant BICX102
ee BioCorRx BioCorRx® Pharmaceuticals Naltrexone Implant BICX102 — for the treatment of opioid and alcohol use disorders Acquired North American rights to new implant formulations and Prodetoxone study data in 2016* * Extended release implant providing a therapeutic effect and maintain plasma levels
Slide 14: BioCorRx Pharmaceuticals: Naltrexone Injectable BICX101
EEE BioCorRxe§ BioCorRx® Pharmaceuticals Naltrexone Injectable BICX101 — for the treatment of opioid and alcohol use disorders + Partnered with Therakine to complete development of a new injectable version of naltrexone using underlying patented and patent pending technology * Utilizing Therakine’s
Slide 15: Competitive Landscape — Addiction Implants
* BioCorRx Competitive Landscape — Addiction Implants Titan Pharmaceuticals (VASDAQ:TTNP) and Braeburn Pharmaceuticals Current buprenorphine implant product: FDA approved buprenorphine implant in May 2016- six- month subdermal implant developed by Titan Pharmaceuticals Braeburn is developing a one w
Slide 16: Competitive Landscape — Naltrexone
EOE BioCorRxef Competitive Landscape — Naltrexone Vivitrol® (Alkermes PLC, NASDAQ:ALKS) Long lasting injectable naltrexone product: - FDA approved sustained release naltrexone injection - lasts up to 30 days «Strong demand - over ~$200 million in sales in 2016 - Parent Company Alkermes ~$9 billion m
Slide 17: Key Advantages of Naltrexone Implant BICX102
LE ic CorRx Key Advantages of Naltrexone Implant BICX102 Advantages over buprenorphine implant: ¥ Addresses both alcoholism and opioid addiction Y Biodegrades eliminating the need to remove and replace v Non-addictive active pharmaceutical ingredient v Known to be effective against other obsessive c
Slide 18: R&D & FDA Objectives & Milestones
BioCorRxel R&D & FDA Objectives & Milestones * Retained Dr. David Gastfriend — previously served as VP of Scientific Communications for Alkermes; heavily involved with Vivitrol * Retained Dr. Bal S. Brar as a lead drug development study design consultant — over 25 years of experience for drug and de
Slide 19: R&D & FDA Objectives & Milestones (cont.)
BioCorRx R&D & FDA Objectives & Milestones (cont.) * Retained Innovative Science Solutions, LLC, a leading scientific consulting firm, to help guide the Company’s regulatory strategy for FDA submission + Held FDA Pre-IND meeting on January 24, 201 + 505(B)(2) pathway deemed acceptable by FDA + Asare
Slide 20: 505(b)(2) Advantages / Cost / Pathway
505(b)(2) Advantages / Cost /Pathway* + 505(b)(2) helps avoid unnecessary duplication of studies already performed on a previously approved (“reference” or “listed”) drug + Gives the FDA express permission to rely on data not developed by the NDA applicant * Less expensive and faster route to approv
Slide 21: Revenue Forecast: Implant/sustained release naltrexone
BioCorRxe Recavery Program Revenue Forecast: Implant/sustained release naltrexone (BICX102) Near-Term Mid-Term Long-Term 1/2021 2022/2023 5+ Years Market Penetration 1% 2% 3% + Revenue $88-245M $386-540M $711M+ + Conservative assumptions based on current naltrexone reimbursement + Potential for high
Slide 22: Non-Addictive Medication
Non-Addictive Medice
Slide 23: The BioCorRx Recovery Program — Non-Addictive MAT
SSS sss ss) BioCorRxe The BioCorRx® Recovery Program — Non-Addictive Medication-Assisted Treatment (MAT) Proprietary Naltrexone Implant! - cleared for use under state and federal compounding rules + Implant inserted in fatty tissue of abdomen + Simple outpatient procedure by licensed medical profess
Slide 24: BioCorRx Recovery Program: A Fully Integrated 52-week Program
ee BioCorRxef BioCorRx® Recovery Program: A Fully Integrated 52-week Program 52-Weeks Outpatient Program Medical Support & Medication Assisted Treatment (MAT)
Slide 25: BioCorRx Recovery Program vs Traditional Modalities
SSS sss ss) BioCorRxe BioCorRx® Recovery Program vs Traditional Modalities OTCOB:BICK BioCorRx® Recovery Program Y Y x ¥: Alcoholics Anonymous Y/N : y. In House Rehab 25
Slide 26: Target Business Model - MAT
Ne FiO ConRxal Recovery Program Target Business Model - MAT Near-Term Long-Term 1-2 Years S+ Years Revenue $35M $710 $12.18M Gross Margin 50-75% 75-80% 80% EBITDA Margin 10-40% 40-50% 50-60% Specific fees charged by providers and collected by BioCorRx are confidential and vary based on region and ot
Slide 27: Corporate Profile
Buses _ Bicor Orporate Profi le cused se
Slide 28: Management
ee 7) Management BioCorRxeg Brady Granier, BSN: CEO/President, Director + 4years with BioCorRx Inc.; repositioned company as leader in the industry with the acquisition of TheraKine technology and R&D initiative, assembled a team of addiction experts worldwide, extensive experience with treatment of
Slide 29: Contact
SSS sss ss) BioCorRxe Contact Management Brady Granier CEO/President brady@BioCorRx.com Lourdes Felix CFO/COO If@BioCorRx.com OTCOB:BICK BioCorRxef 2390 E. Orangewood Ave. Suite 575 Anaheim, CA (714) 462-4880 www.BioCorRx.com www.beataddiction.com
Slide 30: Appendix: Patent Portfolio
FC O2Rx Appendix: Patent Portfolio Applicant Description Hydrophobic drug-delivery material, method for ‘TheraKine, Ltd. manufacturing thereof and methods for delivery of a drug- elvery composition ‘Hydrophobic drug-delivery_ material, method for ‘TheraKine, Ltd. manufacturing thereof and methods fo
Slide 31: Appendix: Patent Portfolio Continued
FC oxRx Appendix: Patent Portfolio Continued US. Patent No./Patent Applicant Description Application Date Approval Date Application No. **_ Therakine, Lid. ee ee YY 20/6/2035 pending PCT/USS/54229 Therakine, Lid. Fw upenrabe Morice 20/7/2014 pending 62/060,654 Europe Patent ‘Application No. Applican